Cerus Corporation provided product revenue guidance for the year 2021. For the year, the company forecasts 15% to 20% revenue growth of approximately $106 million to $110 million in product revenue globally. And that anticipates some modest contribution from its pathogen-reduced cryoprecipitated fibrinogen complex product, but that will really take place in the second half of the year 2021.